STAT3 and ovarian cancer: Besides, although inhibiting the SRC pathway or STAT3 had negligible effects on each other, combined treatment with both JAKi and SRCi led to substantial inhibition of both pathways and exhibited much stronger antitumor activities against human ovarian cancer cells40.